Ribosomes, the molecular machines that translate genetic information into proteins, face an unexpected obstacle when they build proteins embedded in cell membranes. Researchers at the Center for Molecular Medicine Cologne and the CECAD Cluster of Excellence on Aging Research have shown that highly hydrophobic membrane-spanning segments can cause ribosomes to stall before protein synthesis is complete. The stalled products are then recognized by the ribosome-associated protein quality control pathway, or RQC, and targeted for rapid destruction. The findings, published in The EMBO Journal under the title “Principles of ribosome-associated protein quality control during the synthesis of CFTR,” identify a fundamental vulnerability in the production of transmembrane proteins and reveal a physiological role for quality-control systems that has remained incompletely understood.
Every human cell produces thousands of different proteins, each of which must acquire the correct structure and reach the correct location to function. Around one-quarter of human proteins are transmembrane proteins, meaning that they contain one or more segments that cross a lipid bilayer. These proteins form channels, receptors, transporters, and adhesion molecules, allowing cells to communicate, exchange substances, and respond to their surroundings. Their production is unusually demanding because the ribosome must synthesize a protein whose chemical properties are compatible with two very different environments: the watery interior of the cell and the oily interior of the membrane. The hydrophobic sequences that eventually reside within the membrane can therefore create a difficult manufacturing problem while they are still emerging from the ribosome.
Protein synthesis begins when a ribosome reads an mRNA molecule and links amino acids together in the order specified by the genetic code. As the growing chain exits the ribosome, it is guided toward cellular machinery that helps it fold and, in the case of membrane proteins, insert into a membrane. If translation proceeds normally, the ribosome reaches the end of the coding sequence and releases a completed protein. However, the Cologne team found that some ribosomes translating highly hydrophobic membrane-spanning segments become arrested during this process. The arrest is not necessarily caused by a mutation or an external toxin. Instead, it can arise from the intrinsic physical and biochemical challenges of handling hydrophobic sequences during translation.
A stalled ribosome presents a serious problem for the cell. It remains attached to an incomplete protein chain and may block the mRNA from being translated by other ribosomes. The unfinished protein is also unlikely to fold or function correctly and could become a source of toxic aggregates if it were released and allowed to accumulate. The RQC pathway resolves this danger by detecting translation arrest, separating the stalled ribosome complex, and directing the incomplete protein toward degradation. In this way, RQC acts before a defective product can leave the ribosome and interfere with cellular processes. When this surveillance system fails, truncated or misfolded proteins can build up, a condition linked to neurodegeneration and to the broader decline in cellular maintenance associated with aging.
“RQC dysfunction leads to neurodegeneration and contributes to systemic health decline during aging,” said principal investigator Dr Débora Trentini. Although researchers have established many of the molecular steps involved in ribosome-associated quality control, the precise causes of ribosome stalling in living cells have been less clear. The new study indicates that difficult-to-translate membrane proteins are an important physiological trigger. Rather than treating stalling only as an abnormal event caused by damaged mRNA or unusual sequences, the findings show that it can be a predictable consequence of normal protein production. The RQC pathway therefore appears to serve not only as an emergency response to rare translation failures, but also as a routine safeguard for proteins whose architecture makes synthesis intrinsically hazardous.
To investigate this problem in a medically relevant system, the researchers focused on CFTR, the cystic fibrosis transmembrane conductance regulator. CFTR is a chloride channel located in epithelial cell membranes. By moving chloride ions across these membranes, it helps regulate salt concentration, water movement, and the hydration of secretions in organs including the lungs, pancreas, and intestines. Mutations that reduce the amount or activity of functional CFTR cause cystic fibrosis, a hereditary disease in which thickened mucus and impaired epithelial transport can damage multiple organs. Because the disease is already associated with insufficient CFTR function, any loss during the protein’s production could have important consequences for the final number of channels available at the cell surface.
The team developed a reporter system to determine how often ribosomes complete CFTR synthesis. They inserted the CFTR coding sequence between two fluorescent protein sequences, one producing a green signal and the other producing a red signal. If a ribosome translates the complete mRNA without interruption, both fluorescent proteins are produced and the signals are approximately balanced. If translation stops within the CFTR sequence, the upstream green marker can still be made, while the downstream red marker is absent or greatly reduced. A stronger green-than-red signal therefore provides an indirect measurement of translation arrest. After introducing the engineered mRNA into cultured human cells, the researchers detected a small but measurable fraction of CFTR translation events that failed to reach completion.
The arrests occurred even when CFTR lacked disease-associated mutations, indicating that the difficulty is built into the normal protein rather than being exclusively a consequence of pathogenic variants. The researchers also found that cystic fibrosis drug therapies examined in the study did not eliminate this translation problem. This observation does not show that the medications are ineffective; current treatments can improve CFTR folding, trafficking, stability, or channel activity depending on the mutation. Instead, it points to a separate stage of the protein’s life cycle at which some molecules may be lost before they can be folded, transported, or pharmacologically corrected. Translation arrest and RQC activation could therefore help determine how much CFTR is produced in the first place.
The findings may eventually influence strategies for treating genetic diseases caused by membrane-protein defects. Most therapeutic approaches for cystic fibrosis focus on correcting the behavior of CFTR after it has been synthesized, for example by helping mutant proteins fold, reach the cell surface, or remain active. The new work suggests that future interventions might also consider the ribosome and the early stages of protein production. In principle, it may be possible to modify the sequence context surrounding difficult membrane-spanning regions, adjust the activity of quality-control factors, or develop approaches that help ribosomes negotiate problematic hydrophobic segments without allowing defective products to accumulate. Such possibilities remain speculative, and weakening RQC indiscriminately could be dangerous because the pathway protects cells from many toxic translation products. Nevertheless, identifying the physical origin of stalling provides a foundation for investigating more selective interventions.
The study also places membrane-protein synthesis within a wider biological picture. Cells must constantly balance efficiency with accuracy: producing enough proteins to sustain growth and function while eliminating molecules that are incomplete or incorrectly assembled. Ribosome-associated quality control is central to that balance because it acts at the moment a problem occurs, before a defective protein has spread through the cell. The Cologne researchers’ results show that even a normal, essential protein such as CFTR can challenge this system during routine synthesis. By revealing why ribosomes stall and how cells respond, the work opens a new line of research into the connection between translation, membrane biology, inherited disease, and age-related loss of protein homeostasis.
Subject of Research: Cells
Article Title: Principles of ribosome-associated protein quality control during the synthesis of CFTR
Web References: https://doi.org/10.1038/s44318-026-00883-0
References: The EMBO Journal, DOI: 10.1038/s44318-026-00883-0
Keywords: Ribosome-associated protein quality control, RQC, ribosome stalling, transmembrane proteins, CFTR, cystic fibrosis, protein synthesis, protein degradation, membrane proteins, cellular protein quality control
